Should BNY Mellon US Mid Cap Core Equity ETF ( BKMC ) Be on Your Investing Radar?
Style Box ETF report for ...
Is IPF the Next Big Market Opportunity for United Therapeutics?
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
6 Stocks Poised For Potential Acquisition In The Next 12 Months, According To Goldman Sachs, Including A 200% YTD Gainer - ( AACT ) , Walt Disney ( NYSE:DIS )
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. The bank reported that the total dollar value of M&A deals has risen 29% year-over-year, with deal volumes in 2025 climbing 8%. The bank projects an additional 15% increase in new ...
Spotlight on Insmed: Analyzing the Surge in Options Activity - Insmed ( NASDAQ:INSM )
Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed ( NASDAQ: INSM ) revealed 29 unusual trades. Delving into the details, we found 27% of traders were bullish, while 55% showed bearish tendencies.
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 10.19% on an annualized basis producing an average annual return of 23.63%. Currently, Insmed has a market capitalization of $30.45 billion.
4 ETFs To Buy For A Strong Q4 - And 1 To Avoid 4 ETFs To Buy For A Strong Q4 - And 1 To Avoid - Alphabet ( NASDAQ:GOOG ) , SPDR Gold Trust ( ARCA:GLD )
There's a massive shift in the markets heading our way, one you may not have noticed. See, markets often rally in the summer. That's not unusual. But when that rally sticks around into September - usually the worst month of the year for stocks - it's time to pay attention.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
3 Stocks To Consider After Google's Favorable Anti-Trust Ruling - Alphabet ( NASDAQ:GOOG ) , Apple ( NASDAQ:AAPL )
A federal judge's decision this week, allowing Google GOOG to maintain its Chrome browser and dominant search business, has Wall Street breathing a sigh of relief. The ruling removes the near-term threat of a forced breakup and refocuses the fight for digital search dominance in the marketplace, ...
UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals
United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Apollo Asset Management ( NYSE:APO ) , Air Lease ( NYSE:AL )
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Air Lease Corporation AL rose sharply during Tuesday's session after the aircraft lessor said it will be acquired by a newly formed Dublin-based holding company backed by Sumitomo Corp.
Israel Englander's Millennium Goes All-In On Crypto And Healthcare While Rebalancing Big Tech Bets: Bitcoin ETF And Palantir Stakes Soar In Q2 - iShares Bitcoin Trust ( NASDAQ:IBIT ) , Palantir Technologies ( NASDAQ:PLTR )
Millennium Management LLC, led by billionaire Israel Englander, made bold moves in its portfolio according to its second-quarter 13F filings, significantly boosting exposure to cryptocurrency and healthcare while strategically rebalancing its big tech holdings.
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 5.7% on an annualized basis producing an average annual return of 18.27%. Currently, Insmed has a market capitalization of $27.41 billion.
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday - Alzamend Neuro ( NASDAQ:ALZN ) , Analog Devices ( NASDAQ:ADI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised I-Mab IMAB price target from $5 to $6. Needham analyst Gil Blum maintained a Buy rating.
Lung Disease-Focused Insmed 'Must-Own' Name For Investors - Insmed ( NASDAQ:INSM )
Insmed's Brinsupri was approved as the first treatment for bronchiectasis in patients 12 and older. William Blair projects Insmed's peak sales could reach $15 billion by 2035. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Legendary Investor Stanley Druckenmiller Made Huge AI And Chipmaker Bets In Q2 - Here's What He Knows That You Don't - Broadcom ( NASDAQ:AVGO ) , Amazon.com ( NASDAQ:AMZN )
Legendary macro investor Stanley Druckenmiller made significant shifts in his portfolio in the second quarter, establishing major new positions in artificial intelligence and semiconductor leaders, rotating into large-cap banks, and placing a broadly bullish bet on the U.S. stock market, ...
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday - Celanese ( NYSE:CE ) , Carlyle Group ( NASDAQ:CG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim cut Eli Lilly and Company LLY price target from $942 to $875.
Why Is Insmed Stock Trading Higher Today - Insmed ( NASDAQ:INSM )
Brinsupri cuts annual NCFB exacerbations by up to 21% in Phase 3 trial. First FDA-approved treatment for 500,000 U.S. NCFB patients. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → The U.S.
Don't Overlook Insmed ( INSM ) International Revenue Trends While Assessing the Stock
Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 3.51% on an annualized basis producing an average annual return of 15.22%. Currently, Insmed has a market capitalization of $20.78 billion.
Insmed ( INSM ) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Fortrea Holdings Inc. ( FTRE ) Beats Q2 Earnings and Revenue Estimates
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +216.67% and +12.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Insmed ( INSM ) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
The 5 Most Volatile Stocks This Week And How To Trade Them - Centene ( NYSE:CNC ) , Joby Aviation ( NYSE:JOBY )
After focusing on earnings for the bulk of last week, we're going to shift gears a bit today. This week, the spotlight is on implied volatility ( IV ) and, more importantly, five stocks poised to explode in the next week. We've discussed IV quite often and how, in many cases, it's easier to ...
Will Insmed ( INSM ) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should iShares Russell 2000 ETF ( IWM ) Be on Your Investing Radar?
Style Box ETF report for ...
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 2.94% on an annualized basis producing an average annual return of 14.32%. Currently, Insmed has a market capitalization of $18.67 billion.
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative' - First Majestic Silver ( NYSE:AG ) , Insmed ( NASDAQ:INSM )
"I'm going to say no, too speculative," Cramer on Ouster. Jim Cramer says Tempus AI is another company that's just losing money "hand over fist." Get daily-updated rankings across momentum, growth, value, trends, and quality to spot the strongest stocks in any market.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 3.38% on an annualized basis producing an average annual return of 14.93%. Currently, Insmed has a market capitalization of $18.66 billion.
What Does the Market Think About Insmed? - Insmed ( NASDAQ:INSM )
Insmed's INSM short percent of float has risen 5.99% since its last report. The company recently reported that it has 17.46 million shares sold short, which is 10.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.27 days to cover their ...
Last week's top gainer large cap stocks - Halliburton ( NYSE:HAL ) , Oracle ( NYSE:ORCL ) , AST SpaceMobile ( NASDAQ:ASTS )
Insmed surged 34.1% after its Phase 2b study on treprostinil powder met all endpoints, prompting analyst price hikes. Oracle rose 23.7% on strong Q4 earnings and upbeat guidance, with multiple analysts raising their price targets.
United Therapeutics ( UTHR ) Soars 3.5%: Is Further Upside Left in the Stock?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently, Insmed has a market capitalization of $17.70 billion.
Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast - Insmed ( NASDAQ:INSM )
TPIP data "exceeded even our bullish outlook," says BofA, citing strong efficacy and promising safety profile. BofA raises Insmed price target to $109, citing upcoming catalysts including brensocatib's FDA decision by Aug. 12.
Insmed Stock Jumps 29% on Encouraging PAH Study Results
INSM eyes the next steps as TPIP hits all endpoints in the PAH study, setting the stage for late-stage trials and broader potential in lung disease.
Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Datadog ( NASDAQ:DDOG ) , Academy Sports ( NASDAQ:ASO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Lumentum Holdings Inc. LITE price target from $100 to $105.
Should iShares Russell 2000 Growth ETF ( IWO ) Be on Your Investing Radar?
Style Box ETF report for ...
3 Stocks With The 'Insider Advantage' - EVI Industries ( AMEX:EVI ) , Hamilton Beach Brands ( NYSE:HBB )
There's a well-worn line in value investing circles that says, "I want to invest with people who eat their own cooking." In other words, you want the people running the company to have a meaningful chunk of their net worth tied up in the business.
Dow Gains 50 Points; US Small Business Optimism Index Rises In May - Casey's General Stores ( NASDAQ:CASY ) , Calavo Growers ( NASDAQ:CVGW )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday. The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S&P 500 also rose, gaining, 0.29% to 6,023.46. Energy shares jumped by 1.9% on Tuesday.
Should Vanguard Russell 2000 ETF ( VTWO ) Be on Your Investing Radar?
Style Box ETF report for ...
Should Vanguard Russell 2000 Growth ETF ( VTWG ) Be on Your Investing Radar?
Style Box ETF report for ...
Should Global X Russell 2000 ETF ( RSSL ) Be on Your Investing Radar?
Style Box ETF report for ...
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 5 years by 6.26% on an annualized basis producing an average annual return of 20.05%. Currently, Insmed has a market capitalization of $12.09 billion.
How Do Investors Really Feel About Insmed? - Insmed ( NASDAQ:INSM )
Insmed's INSM short percent of float has risen 4.37% since its last report. The company recently reported that it has 15.78 million shares sold short, which is 8.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.09 days to cover their ...
Is the Vanguard Russell 2000 Index Fund ETF a Buy Now?
The Russell 2000 is supposed to outperform in bull markets, but that hasn't been the case recently. Since the start of 2023, the Vanguard Russell 2000 Index Fund ( NASDAQ: VTWO ) -- an exchange-traded fund ( ETF ) -- is up just 19% compared to a 55% gain for the S&P 500.
Should iShares Russell 2000 ETF ( IWM ) Be on Your Investing Radar?
Style Box ETF report for ...
Unlocking Insmed ( INSM ) International Revenues: Trends, Surprises, and Prospects
Examine the evolution of Insmed's (INSM) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Evergy ( NASDAQ:EVRG ) , Black Hills ( NYSE:BKH )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Kelly Shi initiated coverage on Insmed Incorporated INSM with a Buy rating ...
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Insmed ( NASDAQ:INSM )
Insmed INSM has outperformed the market over the past 5 years by 6.96% on an annualized basis producing an average annual return of 21.46%. Currently, Insmed has a market capitalization of $11.88 billion.
